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Abstract 
 
Background: One of the human and animal models of migraine is the systemic 
administration of the nitric oxide donor (NO) nitroglycerin (NTG). NO can provoke 
migraine like attacks in migraineurs and initiates a self-amplifying process in the 
trigeminal system, probably leading to central sensitization. Recent studies suggest that 
the endocannabinoid system is involved in nociceptive signal processing and 
cannabinoid receptor (CB) agonists are able to attenuate nociception in animal models 
of pain. 
Aim: The purpose of the present study was to investigate the modulatory effects of a 
CB agonist anandamide (AEA) on the NTG-induced expression of transient receptor 
potential vanilloid type 1 (TRPV1), neuronal nitric oxide synthase (nNOS), nuclear 
factor kappa B (NF-κB), cyclooxygenase-2 (COX-2) and kynurenine aminotransferase-
II (KAT-II) in the upper cervical spinal cord (C1-C2) of the rat, where most of the 
trigeminal nociceptive afferents convey. 
Methods: Half hour before and one hour after NTG (10 mg/kg) or placebo injection, 
adult male Sprague-Dawley rats (n=44) were treated with AEA (2x5 mg/kg). Four hours 
after placebo/NTG injection, the animals were perfused and the cervical spinal cords 
were removed for immunohistochemistry and Western blotting. 
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Results and conclusion: Our results show that NTG is able to increase TRPV1, nNOS, 
NF-κB, COX-2 and decrease KAT-II expression in the C1-C2 segments. On the other 
hand, we have found that AEA modulates the NTG-induced changes, thus it influences 
the activation and central sensitization process in the trigeminal system, probably via 
CBs. 
 
Key words: migraine; trigeminal system; nitroglycerin; anandamide; TRPV1; nNOS; 
NF-κB; COX-2; KAT-II 
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Introduction 
Migraine belongs to the group of primary headaches, and it is one of the most abundant 
neurological syndromes, which affects 15% of the European population (1). Despite 
intensive research, the exact pathomechanism of the disorder is not fully understood, 
but it is well-known that activation and sensitization of the trigeminal system is 
essential during the attack (2). Continuous activation of peripheral trigeminal afferents 
leads firstly to peripheral (first order) sensitization. Sustained inputs can lead to second 
order, and ultimately to third order central sensitization (3). Previous data have shown, 
that after the onset of central sensitization during the migraine attack, the acute 
treatment becomes less effective (4). Although, this theory has been contested recently, 
stating that the severity of headache might be a better indicator, than the symptoms of 
sensitization (5, 6), it is generally accepted that the latter plays an essential role in the 
genesis of migraine (7). 
One of the models of migraine is the systemic administration of nitroglycerin (NTG), 
generating a short lasting headache in humans via the rapid vasodilatatory effect of 
nitric oxide (NO) followed by a typical migraine without aura in migraine patients (8).  
In rats, NTG is able to increase c-Fos-immunoreactivity in the caudal trigeminal nucleus 
(TNC) suggesting the activation of the second order trigeminal neurons there (9). NO is 
also involved in the central sensitization process in the trigeminal system (10), probably 
Field Code Changed
Page 5 of 47
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
acting via the activation of trigeminal Aδ and C fibres, since the destruction of the latter 
with capsaicin abolishes the effect of NTG (11).  
Cannabinoid receptors (CB) are G-protein-coupled receptors, which have two subtypes: 
CB1 and CB2. CB1 is present in the central nervous system, liver, lung and CB2 is 
expressed primarily in the immune system (12).  
Animal models of pain have shown that fluctuations in the endocannabinoid levels in 
the nervous system are related to pain processing and antinociception (13). CB1 is 
present in the trigeminal ganglion (TG) and on the axon terminals of primary sensory 
neurons in the nociceptive areas in the spinal cord in rats (14). CB1 is able to inhibit the 
responses of trigeminal neurons with A- and C-fiber inputs from the dura mater (15), 
pointing to the importance of the endocannabinoid system in pain processing (16).  
Although the psychoactive properties of cannabinoids (17), restrict their therapeutic 
application, the interactions between the endocannabinoid system and pain mediation is 
intensively studied in several laboratories. 
N-Arachidonylethanolamide or anandamide (AEA) is the first discovered 
endocannabinoid, and is an agonist of CBs and transient receptor potential vanilloid 
type 1 (TRPV1), which is a nonselective cation channel activated by numerous stimuli, 
such as heat and vanilloids (18, 19). AEA has vasodilatatory actions (20), which is not 
mediated by CBs (21). It is well known that AEA is able to reduce NTG-induced 
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hyperalgesia and c-Fos expression in the TNC in rats (22), which means that AEA is 
capable of modulating the activation of the trigeminal system.  
TRPV1 is present in the spinal cord and is considered as a molecular integrator of 
chemical and physical stimuli that elicit pain (23). In addition, NO donors can activate 
TRPV1 resulting in an increase of intracellular calcium concentration in different cell 
types (24, 25), which suggests that TRPV1 may be modulated by NO. 
NO is synthesized from arginine by nitric oxide synthase, neuronal isoform of which 
(nNOS) has an outmost importance in nociception and sensitization and it is present in 
the trigeminal system (26). NO donors may trigger a self-amplifying process at the level 
of central projection site of the trigeminal system by increasing endogenous NO 
synthesis, which might be relevant in central sensitization phenomenon (7). 
Nuclear factor kappa B (NF-κB) has a crucial role in inflammation process by 
controlling many genes including cytokynes. Several studies have shown that 
proinflammatory cytokynes contribute to the development of pain and hyperalgesia 
(27). Cyclooxygenase-2 (COX-2) is present in the dorsal horn of spinal cord too and it 
has a substantial role in the processing of pain (28). Gao and Duan have found that 
COX-2 expression increased in the TNC after orofacial nociception (29). 
Kynurenine aminotransferase-II (KAT-II) is a key enzyme in the kynurenine pathway, 
which converts L-kynurenine (L-KYN) to kynurenic acid (KYNA), a known ionotropic 
glutamate receptor antagonist molecule (30), which can also block α-7-nicotinic 
Field Code Changed
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acetylcholine receptors (31). In NTG-induced animal model of migraine L-KYN, 
KYNA and KYNA analogues inhibited the trigeminal activation and sensitization (32-
34). 
Thus modulatory effects of cannabinoids can be suggested on trigeminal activation both 
on peripheral and central levels. In the present paper we studied the effect of NTG 
injection on the TRPV1, nNOS, NF-κB, COX-2 and KAT-II expression levels in the 
superficial laminae of C1-C2 and its modulation by CB agonist AEA. 
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Materials and methods 
Animals 
The procedures utilized in this study followed the guidelines for the Use of Animals in 
Research of the International Association for the Study of Pain and the directive of the 
European Economic Community (86/609/ECC). They were permitted by the Committee 
of the Animal Research of Unive sity of Szeged (I-74-12/2012) and the Scientific 
Ethics Committee for Animal Research of the Protection of Animals Advisory Board 
(XI./352/2012). 44 adult male Sprague-Dawley rats weighing 200-250 g were used. The 
animals were raised and maintained under standard laboratory conditions with tap water 
and regular rat chow available ad libitium on a 12 hour dark-12 hour light cycle. 
Drug administration 
The animals were divided into four groups (n=6 per group for immunohistochemistry, 
n=5 per group for Western blot analysis). The animals in the first group, called placebo 
group, received only the vehicle solution (physiological saline) as treatment. In the 
second group, the rats were treated with an intraperitoneal injection of NTG (10 mg/kg 
bodyweight, Pohl Boskamp). In the third and fourth group, animals received 
intraperitoneal AEA (2x5 mg/kg bodyweight, Simga Aldrich) half hour before and one 
hour after the placebo or NTG treatment. Greco and colleagues have demonstrated that 
single 20 mg/kg doses of AEA before the NTG administration is able to reduce NTG-
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induced c-Fos expression in the caudal part of spinal trigeminal nucleus (22). Since in 
our other running experiments (not reported here) we obtained results showing the 
efficacy of AEA in lower dosages we used 2x5 mg/kg of AEA in this context using two 
injections due to the short half-life of the drug (35). AEA was dissolved in physiological 
saline. In the case of the first and second groups, animals were treated with 
physiological saline instead of AEA.  
Immunohistochemistry 
Four hours after the placebo/NTG injection, the rats were perfused transcardially with 
100 mL phosphate-buffered saline (PBS, 0.1 M, pH 7.4), followed by 500 mL 4% 
paraformaldehyde in phosphate-buffer under chloral hydrate (0.4 g/kg bodyweight) 
anesthesia. The C1-C2 segments of the cervical spinal cord between -5 and -11 mm 
from the obex were removed and postfixed overnight for immunohistochemistry in the 
same fixative. After cryoprotection, 30 µm cryostat sections were cut and serially 
collected in wells containing cold PBS. The free-floating sections were rinsed in PBS 
and immersed in 0.3% H2O2 in methanol or PBS for 30 minutes. After several rinses in 
PBS containing 1% Triton X-100, sections of C1-C2 were kept for overnight at room 
temperature in anti-TRPV1 antibody (Santa Cruz, s.c.28759) at a dilution of 1:500, or 
for two nights at 4 °C in anti-nNOS antibody (EuroProxima, 2263B220-1) at a dilution 
of 1:5000, or for two nights at 4 °C in anti- NF-κB antibody (Abcam, ab97726) at a 
dilution of 1:100. The immunocytochemical reaction was visualized by the Vectastain 
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avidin-biotin kit of Vector Laboratories (PK6101), and nickel ammonium 
sulphate-intensified 3,3’-diaminobenzidine. The specificity of the immune reaction was 
controlled by omitting the primary antisera. 
Western blot analysis 
Four hours after the placebo/NTG injection, the animals were perfused transcardially 
with 100 mL PBS and the dorsal horns of C1-C2 segments were extracted. Until the 
measurements, the samples were stored at −80 °C. The samples were sonicated in ice 
cold lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 0.1% igepal, 0.1% cholic 
acid, 2 µg/mL leupeptin, 2 mM phenylmethylsulphonyl fluoride, 1 µg/mL pepstatin, 2 
mM EDTA and 0.1% sodium dodecyl sulphate. The lysates were centrifuged at 12 000 
RPM for 10 minutes at 4 °C and supernatants were aliquoted and stored at -20 °C until 
use. Protein concentration was defined with BCA Protein Assay Kit using bovine serum 
albumin as a standard. Previous to loading, each sample was mixed with sample buffer, 
and denaturated by boiling for 3 minutes. Equal amounts of protein samples (20 
µg/lane) were separated by standard SDS polyacrylamide gel electrophoresis on 10% 
Tris-Glycine gel and electrotransferred onto Amersham Hybond-ECL nitrocellulose 
membrane (0.45 µm pore size). We used the Page Ruler Prestained Protein Ladder (10-
170 kDa) to define approximate molecular weights. Following the transfer, membranes 
were blocked for one hour at room temperature in Tris-buffered saline containing 
Tween 20 (TBST) and 5% non fat dry milk powder. Then, they were incubated in TBST 
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containing 1% non fat dry milk and nNOS antibody (BD Biosciences, 610308, dilution: 
1:2000, incubation: overnight at room temperature), or COX-2 antibody (Proteintech, 
12375-1-AP, dilution: 1:1000, incubation: overnight at room temperature), or KAT-II 
antibody (Santa Cruz, sc-67376, dilution: 1:10 000, incubation: overnight at room 
temperature) or β-actin antibody (Calbiochem, CP01, dilution: 1:100 000, incubation: 
overnight at room temperature). Next day, membranes were incubated in TBST 
containing 1% non fat dry milk and horseradish peroxidase-conjugated anti-rabbit or 
anti-mouse secondary antibody (Santa Cruz Biotechnology, sc-2030, sc-2031) for two 
hours at room temperature. Protein bands were visualized after incubation of 
membranes with the SuperSignal West Pico Chemiluminescent Substrate using 
Carestream Kodak BioMax Light film. 
Data evaluation 
All evaluations were implemented by an observer blind to the experimental groups. The 
detailed methods were described previously (34-3634, 36, 37). 
Immunohistochemistry (TRPV1, nNOS, NF-κB) 
The photomicrographs of the stained sections of C1-C2 were taken using Zeiss 
AxioImager microscope supplied with an AxioCam MRc Rev.3 camera (Carl Zeiss 
Microscopy, Jena, Germany). 
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The area covered by TRPV1-immunoreactive fibres and nNOS-immunoreactive cells 
was determined by Image Pro Plus 6.2® image analysis software (Media Cybernetics). 
After image acquisition, the laminae I-II in dorsal horn were defined manually as area 
of interest and a threshold grey level was validated with the image analysis software, as 
described in an earlier study (32, 3536). The program calculated the area innervated by 
the immunoreactive fibres and cells as the number of pixels with densities above the 
threshold, the data were expressed as area fractions (%) of the corresponding 
immunolabelled structures. 
We used the unbiased optical disector method to calculate the volume densities of the 
NF-κB-immunoreactive cells (3637). 
Western blot analysis (nNOS, COX-2, KAT-II) 
For densitometric analyses, films were scanned and quantified using Java ImageJ 1.47v 
analysis software (National Institutes of Health). The results were normalized to β-actin. 
Statistical analysis 
Statistical analysis of measurements were performed in SPSS Statistics software 
(Version 20.0 for Windows, SPSS Inc.) using one-way analysis of variance (ANOVA) 
followed by the Tukey or Tamhane post hoc test depending on variances of data, with 
P<0.05 taken as statistically significant. Group values are reported as means ± SEM. 
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Results 
NTG induced an increase in TRPV1 expression in the C1-C2 - AEA inhibited this 
phenomenon  
On transverse sections of the C1-C2 segments, there were abundant TRPV1-positive 
fibres in the superficial layers f the dorsal horn. The TRPV1-immunoreactive area in 
the NTG-treated group was significantly higher compared to the placebo-treated group 
(P<0.05). The NTG-induced increase was attenuated by treatment with AEA (P<0.05). 
(Fig 1.) 
[Insert Figure 1.] 
NTG increased nNOS expression in the C1-C2 and AEA attenuated this effect 
On transverse sections of the C1-C2 segments, nNOS-immunoreactive neurons and 
processes with cytoplasmic staining can be observed in the superficial layers of the 
dorsal horn. In the NTG group, the area fraction of nNOS-immunoreactive structures 
was significantly higher than in the placebo-treated group (P<0.01). AEA treatment 
resulted in a decrease of nNOS-immunopositive structures (P<0.001). (Fig 2.) 
[Insert Figure 2.] 
 
Western blot analysis of the C1-C2 region confirmed the results obtained by nNOS 
immunohistochemistry. A band characteristic of the nNOS protein was identified at 155 
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kDa. Densitometric analyses confirmed that the nNOS bands were significantly 
enhanced (P<0.01) in C1-C2 after NTG administration as compared with the placebo-
treated animals. This effect was blocked by the treatment with AEA (P<0.05). (Fig 3.) 
[Insert Figure 3.] 
NTG treatment enhanced NF-κB expression and AEA mitigated this phenomenon 
In transverse sections of the C1-C2 egion high number of NF-κB-positive cells can be 
seen in the superficial layers of the dorsal horn. In the NTG treated animals the volume 
density of NF-κB-positive cells was significantly higher than in the placebo group 
(P<0.05). This value decreased in the AEA injected group (P<0.05). (Fig 4.) 
[Insert Figure 4.] 
NTG enhanced expression of COX-2 enzyme and AEA inhibited this action 
A band characteristic of the COX-2 protein was identified at 68 kDa in Western blot 
assay. Densitometric analyses showed that the COX-2 bands were significantly 
enhanced (P<0.01) in segments C1-C2 after NTG administration as compared with the 
placebo-treated animals. The effect of NTG was decreased by the AEA treatment 
(P<0.01). (Fig 5.) 
[Insert Figure 5.] 
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NTG decreased KAT-II expression, which was alleviated by AEA 
A band characteristic of the KAT-II protein was referred at 60 kDa in Western blot 
assay. Densitometric analyses confirmed that the KAT-II bands were significantly 
weaker (P<0.05) in segments C1-C2 after NTG administration as compared with the 
placebo-treated animals. This effect was reversed by treatment with AEA (P<0.05). (Fig 
6.) 
[Insert Figure 6.] 
Page 16 of 47
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Discussion 
The present data indicate that NTG treatment activates the trigeminal system and the 
observed changes can be interpreted as a central sensitization phenomenon. The NTG 
induced alterations are reversed by the administration of AEA suggesting the 
involvement of CBs in this process. 
It is generally accepted that the trigeminal pain processing and sensitization is an 
extremely complex phenomena involving numerous cellular and molecular components 
but the associated pathways are not fully known. Figure 7. shows a schematic and 
simplified flow diagram, which indicates that the connections are sometimes indirect 
and the signaling molecules may modulate the complex response at different target 
points. 
[Insert Figure 7.] 
TRPV1 
TRPV1 is present in the terminals of primary sensory neurons in the dorsal part of 
spinal cord (3738) and co-expressed with CB1 (3839). Experimental data indicate that 
TRPV1 contributes to the peripheral sensitization, allodynia and hyperalgesia (3940), 
central blockade of this receptor is able to attenuate central terminal sensitization 
(4041). Our results show that NTG significantly increases TRPV1 expression in the C1-
C2 segments of the rat, thus it may be the indicator of sensitization phenomena in the 
trigeminal system in our experimental setting. 
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It is well evidenced that NO donors can activate TRPV1 in several cell types (24, 4142) 
and in inflammatory pain models increased receptor expression was also reported (4243, 
4344). This indicates that the NTG effect on TRPV1 expression is indirect - it may 
cause neurogenic inflammation (4445), and the inflammatory mediators (- like serotonin 
(5-HT), bradykinin (BK), etc.) - can activate TRPV1 by stimulating trigeminal 
nociceptive neurons (4546). In the animal model of inflammation, Complete Freud’s 
adjuvant increases TRPV1 mRNA expression in the dorsal root ganglion Pro-
inflammatory mediators, such as tumor necrosis factor α, interleukin 1 (IL-1), 
interleukin 6 (IL-6) and BK enhance TRPV1 (4647),. In the animal model of 
inflammation, Complete Freud’s adjuvant increases TRPV1 mRNA expression in the 
dorsal root ganglion (48), this also supports the idea that inflammation upregulates 
TRPV1 expression. To summarize, we may assume that NTG is able to activate TRPV1 
mainly via inflammatory mediators. On the other hand, there are research data 
indicating that systemic administration of calcitonin gene-related peptide (CGRP) 
increases the expression of TRPV1 in the TG of rats (49), which might also play a role 
in this process. 
Concerning the possible mechanisms we have to consider that intravenous injection of 
calcitonin gene–related peptide (CGRP) increases the expression of TRPV1 in TG of 
rats (47). As NTG treatment results in an increased CGRP-release from the primary 
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terminals of the caudal trigeminal nucleus (48), we may assume that NTG is able to 
activate TRPV1 via CGRP-release or/and by inflammatory mediators. 
Our recent data also show that AEA, a CB receptor and TRPV1 agonist attenuates the 
effect of NTG on TRPV1 changes. Activation of ionotropic CBs can result in inhibition 
of nociceptors and antihyperalgesia and antinociception in certain pain models (4950). 
Intrathecal administration of AEA decreases thermal pain sensitivity and its effect can 
be altered with the TRPV1 antagonist capsazepine (5051). AEA may also cause a 
desensitization of TRPV1 in skeletal muscle arterioles (5152), suggesting that AEA is 
able to mitigate TRPV1 activity. On the other hand, AEA can inhibit neurogenic, 
CGRP- and NO-induced dural vasodilatation, and this involves pre- and postsynaptic 
mechanisms (5253). Recent report shows that the AEA level changes are able to 
modulate CGRP mRNA-expression after NTG-treatment in human peripheral blood 
mononuclear cells (5354). We do not know exactly the role of TRPV1 in the AEA 
modulated sensitization process, but based on the available literature data (15, 5455), 
we hypothesize that the role of CB1 is more pronounced than TRPV1 in this context.  
nNOS 
It is known that nNOS is a key player in nociception (5556) and its role in the 
sensitization cascade is intensively studied. In our present experiment administration of 
NTG increased the expression of nNOS in the C1-C2, which is in line with earlier 
results (10). The most probable explanation for this phenomenon is, that NO activates 
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Page 19 of 47
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
small caliber fibres in the trigeminal system and the increase of nNOS expression in the 
second order trigeminal neurons induces a self-amplifying mechanism (10, 11). The 
present results indicate that AEA is able to inhibit this effect. Several studies have 
shown that there is an interaction between NO and cannabinoid system e.g. nNOS and 
CB1 are co-localized in neurons in lamina II of the spinal cord (5657), NTG-induced 
hyperalgesia is associated with a fluctuation of endocannabinoid system in various brain 
areas of rats (22). Our data are in line with Hillard and co-workers findings, who 
reported that CB1 agonists inhibit KCl-induced activation of nNOS in cultured 
cerebellar granule cells (5758). In addition, Carney and co-workers have detected that 
cannabinoid agonist downregulated nNOS protein and mRNA in neuronal cells (5859). 
These data suggest that NTG is able to generate sensitization process and AEA inhibits 
this effect by blocking nNOS. 
 
 
 
NF-κB 
In our experiment NTG increased NF-κB expression in the superficial layers of the 
dorsal horn in the C1-C2 segments. Similar effect was reported by Reuter et al., who 
demonstrated that NTG infusion is able to trigger the activation of NF-κB in dura mater 
(5960). It is not clear how NTG can activate NF-κB-pathway, it might be related to a 
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direct neuronal effect of NTG, or indirect effect via dural inflammation (6061). 
Concerning the cellular mechanisms it is important to note that both TRPV1 and nNOS 
might play a role in this effect. It was shown that Ca2+ influx through TRPV1 may 
modulate the nuclear translocation and increased the activity of NF-κB (6162), on the 
other hand the increase in nNOS expression is accompanied by increased NF-κB 
expression and activation (6263). Furthermore, Sancho and colleagues have noticed that 
AEA inhibits tumor necrosis factor-α-induced activation, by inhibition of a cytokine-
induced cascade (6364). In addition, Nakajima and co-workers have found that AEA 
also blocked lipopolysaccharide-induced activation, suggesting that AEA inhibits 
proinflammatory mediators by blocking NF-κB activation (6465). Tassorelli and her 
group reported that parthenolide (inhibitor of NF-κB) attenuated NTG-induced c-Fos 
activation in TNC (64), which indicates that NF-κB may be important in the NTG-
induced trigeminal activation and its inhibition is able to modulate the nociceptive 
process. Our data reconfirm, that NTG is able to activate NF-κB, thus can trigger 
neurogenic inflammation, which has a key role in sensitization phenomena. 
Furthermore, we detected that AEA is able to reduce this effect. Endocannabinoids 
might operate a negative feedback control over the proinflammatory process by 
suppressing the activation of transcription factors involved in the inflammatory action 
(6566). 
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COX-2 
NO may also cause neurogenic inflammation by increasing NF-κB levels, which may 
lead to the upregulation of COX-2 in inflammatory pain (6667). It is well-known, that 
NSAIDs, which exert their effects through the inhibition of COX-enzymes (6768), are 
effective in the treatment of migraine and tension-type headache (6869). In animal 
studies, it has been shown that COX-2 is involved in the NTG-induced activation and 
sensitization process of the trigeminal system. Pre-treatment with indomethacin (non-
selective COX inhibitor) and NS398 (selective COX-2 inhibitor) reduced the NTG-
induced c-Fos (11), nNOS and calmodulin-dependent protein kinase II alpha 
expression-changes in the TNC (6970, 7071). Tassorelli and colleagues have 
demonstrated that COX-2 expression is increased in the hypothalamus and caudal brain 
stem after NTG injection (7172), thus COX is one of the mediators of NTG-induced 
neuronal activation. Furthermore, NO is able to activate COX-enzymes in fibroblasts, 
probably by an interaction with the iron-hem center of the enzyme (7273). It is 
important to note, that AEA is one of the substrates of COX-2 producing prostaglandin 
and ethanolamids (7374). In our study, we have found that AEA is able to inhibit the 
NTG-induced COX-2 increase. The cellular and molecular background of this effect 
remains to be determined. Our assumption is that it may be associated with a negative 
feedback mechanism, but it is possible that after the cleavage of AEA some metabolites 
may downregulate COX-2 expression. Since AEA is able to reduce cytokine-induced 
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cascade and proinflammatory mediators, it is also possible, that the reduction of the 
inflammatory process is able to downregulate the COX-2 expression. 
KAT-II 
In our experiments NTG decreased KAT-II expression in the C1-C2 segments, which 
may indicate that fluctuation f KAT is involved in the NTG-triggered trigeminal 
activation. Recent studies have shown, that migraine is associated with mitochondrial 
dysfunction (7475). It has also been demonstrated that an NO donor is able to 
downregulate the respiratory chain complex and cause release of the mitochondrial 
cytochrome C, thus causing a mitochondrial dysfunction (7576). The decrease in KAT-
II activity might be associated with mitochondrial damage as shown in the striatum of 
patients suffering in Huntington’s disease (7677). This is in line with our earlier data 
showing, that administration of mitochondrial complex II inhibitor 3-nitropropionic acid 
is able to reduce KAT-II activity in rats (7778). On the other hand, NTG may cause 
neurogenic inflammation and the released pro-inflammatory cytokines can modulate the 
kynurenine pathway (7879), which may also contribute to the change in KAT-II 
expression. Nevertheless, in another model of trigeminal activation (electrical 
stimulation of the TG), decreased KAT-immunoreactivity in dural macrophages, 
Schwann cells and mastocytes was found in rats (7980), suggesting a prominent role of 
this enzyme in the process of trigeminal activation.  
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In the present experiment, we have detected that AEA is able to mitigate the NTG-
induced KAT-II expression decrease. AEA and the other endocannabinoid molecule, 2-
arachidonoylglicerol causes reduction of calcium-induced cytochrome C release from 
mitochondria, protect mitochondria from the cytochrome mediated damage, which leads 
to DNA fragmentation and apoptosis (8081, 8182). Taken together it is possible, that 
NTG may cause mitochondrial dysfunction, and AEA is able to inhibit this effect 
probably by decreasing cytochrome C release. 
Conclusions 
In conclusion, our results show that AEA has modulating effect on central sensitization 
markers in our experimental setting. These data suggest that the endocannabinoid 
system plays a significant role in the cellular mechanism of trigeminal sensitization and 
thus it may modulate the pathomechanism of migraine. 
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Article highlights  
• Systemic administration of nitroglycerin is able to activate and sensitize the 
trigeminal system in rats 
• This phenomenon is reflected by alteration of the expression of biological 
markers (TRPV1, nNOS, NF-kB, COX-2 and KAT-II) of this process 
• Anandamide, a cannabinoid receptor agonist is able to modulate these changes 
caused by nitroglycerin 
• Cannabinoid receptors are involved in the activation and sensitization of the 
trigeminal system 
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 Figure captions 
 
Figure 1. A. Representative photomicrographs of the TRPV1 expression in the C1-C2 
segments. B. Changes in area fractions of TRPV1-immunoreactive fibers in superficial 
laminae I and II of the C1-C2 segments. In the NTG group, the area covered by TRPV1 
was significantly higher than in the placebo group. AEA seemed to block this effect. 
Bargraph data presented here and in succeeding figures are means ± SEM. Scale bar: 
100 µm, *P<0.05 
 
Figure 2. A. Representative photomicrographs of nNOS expression in the C1-C2 
segments. B. Changes in the nNOS-immunoreactive area fractions. In the NTG group, 
the area fraction of nNOS-IR structures was increased compared to the placebo-treated 
group. AEA was able to attenuate this effect. Scale bar: 100 µm, **P<0.01; ***P<0.001 
 
Figure 3. A. Western blot of nNOS and β-actin (loading control) expression in the C1-
C2. B. The quantitative analysis shows that in the NTG group, the relative optical 
density of nNOS specific band was significantly higher than in the placebo group. AEA 
treatment weakened this effect. *P<0.05; **P<0.001 
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Figure 4. A. Photomicrographs of the NF-κB expression in the C1-C2 segment. B. 
Diagram shows that NTG treatment resulted in a significant increase in the volume 
density of NF-κB-immunoreactive cells. This effect was not observed in AEA-injected 
animals. Scale bar: 50 µm, *P<0.05 
 
Figure 5. A. Western blot of COX-2 and β-actin expression in the C1-C2. B. 
Densitometry of the individual bands indicated that in the NTG-treated animals the 
expression of COX-2 was significantly higher than in the placebo group. No such effect 
was seen in the AEA-injected group. **P<0.01 
 
Figure 6. A. Western blot of KAT-II and β-actin expression in the C1-C2. B. 
Quantitative data demonstrate that in the NTG group, the relative optical density of 
KAT-II is significantly lower than in the placebo group. AEA reduced this effect. 
*P<0.05 
 
Figure 7. Schematic illustration of the interactions among the NO-influenced molecules 
involved in the trigeminal pain processing and sensitization showing the possible sites 
of action for cannabinoids. 
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